Announcements Trials
Browse Landscape

Phase

Phase 2 13Phase 1 3Phase 3 1Phase 1/2 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other solid neoplasm 1Breast 1

Conditions

Breast Neoplasms 1Advanced Solid Tumor 1Advanced Solid Malignancies 1

Interventions

Cyclophosphamide 624pembrolizumab 500Paclitaxel 456Gemcitabine 438Carboplatin 435Cisplatin 418Radiotherapy 380fludarabine 365Nivolumab 340Docetaxel 277Bevacizumab 276Irinotecan 257Magnetic Resonance Spectroscopy 242Fluorouracil 228Dexamethasone 225Specimen Handling 221Capecitabine 218Rituximab 205Cytarabine 201Oxaliplatin 200Ipilimumab 199Temozolomide 197Biopsy 196fludarabine phosphate 194Etoposide 181Lenalidomide 176Doxorubicin 175Leucovorin 173Cetuximab 171Injections 170

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × HM781-36B × Clear all
NCT03429101 2021-01-15

A Study of Poziotinib in Combination With T-DM1 in HER2-Positive Breast Cancer

Spectrum Pharmaceuticals, Inc

Phase 1 Terminated
6 enrolled
Breast

Breast Neoplasms

NCT01455571 2014-02-26

Phase I Study to Determine the Maximum Tolerated Dose and to Assess the Safety and Pharmacokinetic Profile of HM781-36B in Patients With Advanced Solid Tumors

Hanmi Pharmaceutical Company Limited

Phase 1 Completed
55 enrolled
Other solid neoplasm

Advanced Solid Tumor

NCT01455584 2013-05-23

Clinical Trial to Determine the MTD of HM781-36B in Patients With Advanced Solid Tumors

Hanmi Pharmaceutical Company Limited

Phase 1 Completed
20 enrolled

Advanced Solid Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡